clinical trial · NCT06538480
Zopa Retreatment and Vector Shedding in Adults With RRP
Recurrent Respiratory PapillomatosisPapillomavirus InfectionPapillomaviridaeZopapogene imadenovec (Zopa)
brief summary
This open-label study evaluates safety, vector shedding, and retreatment efficacy of Zopapogene imadenovec (Zopa) in adults with recurrent respiratory papillomatosis (RRP). Two cohorts will be enrolled (n=30): Cohort 1 to assess the magnitude and duration of adenoviral vector shedding in urine, feces, skin, and nasal tissue; Cohort 2 to assess the complete response rate following retreatment.
started
Jul 11, 2024
primary completion
Dec 2, 2027
completion
Dec 2, 2028
last updated
Dec 15, 2025
official title
Open-Label Study of Zopapogene Imadenovec Retreatment and Vector Shedding Evaluation in Adult Patients With Recurrent Respiratory Papillomatosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol